Similar articles for PMID: 10091033

Year	Number of Results
1940	1
1969	1
1970	1
1986	2
1988	2
1989	3
1990	1
1991	1
1992	4
1993	7
1994	2
1995	7
1996	12
1997	20
1998	23
1999	28
2000	26
2001	22
2002	21
2003	12
2004	11
2005	11
2006	6
2007	7
2008	4
2009	7
2010	9
2011	9
2012	12
2013	4
2014	5
2015	3
2016	7
2017	5
2018	6
2019	9
2020	8
2021	5
2022	11
2023	2
2024	1

1

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

Jones RN, Low DE, Pfaller MA. Jones RN, et al. Diagn Microbiol Infect Dis. 1999 Feb;33(2):101-12. doi: 10.1016/s0732-8893(98)00108-4. Diagn Microbiol Infect Dis. 1999. PMID: 10091033 Review.

2

Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Cormican MG, Jones RN. Cormican MG, et al. Drugs. 1996;51 Suppl 1:6-12. doi: 10.2165/00003495-199600511-00004. Drugs. 1996. PMID: 8724811 Review.

3

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.

Rubinstein E, Bompart F. Rubinstein E, et al. J Antimicrob Chemother. 1997 May;39 Suppl A:139-43. doi: 10.1093/jac/39.suppl_1.139. J Antimicrob Chemother. 1997. PMID: 9511078 Review.

4

Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.

Luh KT, Hsueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW. Luh KT, et al. Antimicrob Agents Chemother. 2000 Dec;44(12):3374-80. doi: 10.1128/AAC.44.12.3374-3380.2000. Antimicrob Agents Chemother. 2000. PMID: 11083643 Free PMC article.

5

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.

Sader HS, Jones RN, Ballow CH, Biedenbach DJ, Cered RF; GSMART Latin America Study Group. Sader HS, et al. Braz J Infect Dis. 2001 Feb;5(1):21-31. doi: 10.1590/s1413-86702001000100004. Braz J Infect Dis. 2001. PMID: 11290311 Free article.

6

Gram-positive resistance: challenge for the development of new antibiotics.

Baquero F. Baquero F. J Antimicrob Chemother. 1997 May;39 Suppl A:1-6. doi: 10.1093/jac/39.suppl_1.1. J Antimicrob Chemother. 1997. PMID: 9511055 Review.

7

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Jones RN, et al. Diagn Microbiol Infect Dis. 1998 Jul;31(3):437-51. doi: 10.1016/s0732-8893(98)80002-3. Diagn Microbiol Infect Dis. 1998. PMID: 9635235

8

Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group.

Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. Pfaller MA, et al. Diagn Microbiol Infect Dis. 1999 Apr;33(4):283-97. doi: 10.1016/s0732-8893(98)00149-7. Diagn Microbiol Infect Dis. 1999. PMID: 10212756

9

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.

Bouanchaud DH. Bouanchaud DH. J Antimicrob Chemother. 1997 May;39 Suppl A:15-21. doi: 10.1093/jac/39.suppl_1.15. J Antimicrob Chemother. 1997. PMID: 9511057 Review.

10

Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Lamb HM, Figgitt DP, Faulds D. Lamb HM, et al. Drugs. 1999 Dec;58(6):1061-97. doi: 10.2165/00003495-199958060-00008. Drugs. 1999. PMID: 10651391 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

329 results

Results by year